August 27, 2016 11:21 AM ET

Capital Markets

Company Overview of Novartis Venture Fund

Company Overview

Novartis Venture Fund is an evergreen fund. It is stage agnostic, engaging in investment from seed-to-growth capital-to-later stage including mezzanine financings. It can also invest in other stages. It focuses on Series A and B for initial investment. The fund prefers to invest in product-and platform-focused biotech, pharmaceutical, and healthcare sectors. It seeks to make equity investments in life sciences companies across biotechnology/biopharma, medical devices, and diagnostics. The fund has primary investment focus on the development of novel therapeutics and platforms. It also looks broadly to invest in all types of healthcare innovation. The fund primarily invests globally primarily...

Postfach

Basel,  4002

Switzerland

Founded in 1996

Phone:

41 61 324 32 67

Fax:

41 61 324 86 79

Key Executives for Novartis Venture Fund

President
Age: 60
Managing Director
Age: 39
Managing Director
Age: 52
Managing Director
Compensation as of Fiscal Year 2016.

Novartis Venture Fund Key Developments

Novartis Venture Fund Presents at BIO Trinity 2016, Apr-25-2016

Novartis Venture Fund Presents at BIO Trinity 2016, Apr-25-2016 . Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom.

Novartis Venture Fund Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016

Novartis Venture Fund Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016. Venue: Hilton Zurich Airport Hotel, 27 Belsize Lane, London | NW3 5AS, United Kingdom. Presentation Date & Speakers: Mar-15-2016, Anja König, Managing Director, Markus Goebel, Managing Director.

Novartis Venture Fund Presents at BBC BD Boston, Mar-09-2016 08:30 AM

Novartis Venture Fund Presents at BBC BD Boston, Mar-09-2016 08:30 AM. Venue: The Westin Copley Place, 10 Huntington Avenue, Boston, MA 02116, United States. Speakers: Christine Brennan.

Similar Private Companies By Industry

Company Name Region
“The Lantern” Research Sagl Europe
2thePoint AG Europe
A&a Bull And Bear Europe
AAA Corporate Finance Advisers AG Europe
Abrir Capital Advisors AG Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 23, 2016
Annexon Biosciences, Inc.
Private Placement
June 20, 2016
F2G Ltd
Private Placement
December 11, 2015
eFFECTOR Therapeutics, Inc.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novartis Venture Fund, please visit www.nvfund.com/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.